The Effect of Doxycycline on Matrix Metalloproteinase Expression and Activity in the Abdominal Aneurysm - Full Text View

Sponsor:	Leiden University Medical Center
Information provided by:	Leiden University Medical Center
ClinicalTrials.gov Identifier:	NCT00538967

Purpose

The matrix metalloproteinase-9 (MMP-9) is considered to play a central role in abdominal aortic aneurysm (AAA) initiation. Doxycycline has direct MMP-9 inhibiting properties in vitro, and it effectively suppresses AAA development in rodents. Observed inhibition of AAA progression, and contradictory findings in human studies evaluating the effect of doxycycline therapy on aortic wall MMP-9 suggest that the effects of doxycycline extend beyond MMP-9 inhibition, and that the effect may be dose dependent.

Condition	Intervention	Phase
Aortic Aneurysm, Abdominal	Drug: doxycycline	Phase II

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Investigator) Primary Purpose: Basic Science
Official Title:	The Effect of Doxycycline on Matrix Metalloproteinase Expression and Activity in the Abdominal Aneurysm

Resource links provided by NLM:

MedlinePlus related topics: Aneurysms Aortic Aneurysm

Drug Information available for: Doxycycline Doxycycline hyclate Doxycycline calcium

U.S. FDA Resources

Further study details as provided by Leiden University Medical Center:

Primary Outcome Measures:

Collagenase mRNA and protein expression [ Time Frame: 2 weeks ]

Enrollment:	60
Study Start Date:	May 2002
Study Completion Date:	August 2005

Arms	Assigned Interventions
No Intervention: 1
Active Comparator: 2 doxycycline 50 mg/day	Drug: doxycycline 2 weeks once daily
Active Comparator: 3 doxycycline 100 mg	Drug: doxycycline 2 weeks once daily
Active Comparator: 4 doxycycline 300 mg	Drug: doxycycline 2 weeks once daily

Detailed Description:

In this clinical trial, we evaluated the effect of two weeks of low (50 mg/day), medium (100 mg/day) or high dose (300 mg/day) doxycycline versus no medication in patients undergoing elective AAA repair. The effect of doxycycline treatment on MMP and cysteine proteases, and their respective inhibitors was evaluated in an integrative approach.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Elective open aneurysm repair

Exclusion Criteria:

Severe kidney and liver dysfunction

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00538967

Locations

Netherlands
Leiden University Medical Center
Leiden, Netherlands, 2300RC

Sponsors and Collaborators

Leiden University Medical Center

Investigators

Principal Investigator:

Jan HN Lindeman, MD, PhD

Leiden University Medical Center

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00538967 History of Changes
Other Study ID Numbers:	P00.146
Study First Received:	October 2, 2007
Last Updated:	October 2, 2007
Health Authority:	Netherlands: Medical Ethics Review Committee (METC)

Keywords provided by Leiden University Medical Center:

Collagenases
MMP
Cathepsins
Doxycycline
Aneurysm

Additional relevant MeSH terms:

Aneurysm
Aortic Aneurysm
Aortic Aneurysm, Abdominal
Vascular Diseases
Cardiovascular Diseases
Aortic Diseases
Doxycycline
Doxycycline hyclate

Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents

ClinicalTrials.gov processed this record on February 12, 2012